Home LiteratureArticle Details
PMID: 40112602 Published · ppublish English Journal Article

LncRNA EMBP1 sponges miR-454-3p to upregulate IRF1 and activate NLRP3-mediated chondrocyte pyroptosis to drive osteoarthritis progression.

International immunopharmacology ·Vol. 153 ·2025-04-24 ·Pages 114460

Ma S, Yu P, Ma J, Liu K, Wang M, Shi P, Duong NTD, Cheng S, Wang S

Abstract

Osteoarthritis (OA) is the most common degenerative joint disease worldwide. Studies have confirmed that pyroptosis is closely associated with the OA onset and progression, particularly via the classical pathway mediated by the NLRP3 inflammasome. However, the intrinsic regulatory mechanisms underlying pyroptosis in OA remain unclear. We conducted RNA sequencing (RNA-seq) analysis on clinical cartilage samples and identified hub genes connecting OA and pyroptosis. We validated NLRP3-mediated pyroptosis activation, evaluated the diagnostic potential of the hub gene, and explored its regulatory role using a papain-induced rabbit OA model and IL-1β-induced chondrocytes. Subsequently, we constructed a competitive endogenous RNA (ceRNA) network based on the hub gene and validated its competitive binding interactions and regulatory function in NLRP3-mediated pyroptosis. Additionally, hub gene interferon regulatory factor 1 (IRF1) serves as a recognized upstream regulator of the novel cell death paradigm PANoptosis, which integrates apoptosis, necrosis, and pyroptosis. We preliminarily explored the potential molecular mechanisms of PANoptosis in OA through clinical sample analysis and in vitro experiments. RNA-seq revealed that IRF1, a hub gene linking OA and pyroptosis, is upregulated in OA cartilage and is associated with NLRP3, consistent with the in vivo and in vitro results. Dual-luciferase assays, clinical sample analysis, and in vitro experiments confirmed the competitive binding of the embigin pseudogene 1 (EMBP1)/miR-454-3p/IRF1 ceRNA network. Silencing EMBP1 increased miR-454-3p, inhibiting IRF1 and NLRP3-mediated pyroptosis in vitro; however, miR-454-3p inhibitor rescue experiments abolished the beneficial effects of si-EMBP1. Furthermore, we preliminarily characterized the occurrence of PANoptosis in OA and provided initial evidence suggesting a potential regulatory role for the EMBP1/miR-454-3p/IRF1 axis in this process. In OA, EMBP1 acts as a sponge for miR-454-3p, inhibiting its negative regulatory effect on IRF1 and exacerbating NLRP3-mediated chondrocyte pyroptosis. Furthermore, EMBP1/miR-454-3p/IRF1-mediated pyroptosis may be integrated into the broader PANoptosis process, interacting with apoptosis and necrosis to influence OA progression.

Keywords
IRF1 NLRP3 Osteoarthritis PANoptosis Pyroptosis ceRNA
MeSH Terms
Animals Osteoarthritis/genetics,pathology,metabolism MicroRNAs/genetics,metabolism Chondrocytes/metabolism,pathology NLR Family, Pyrin Domain-Containing 3 Protein/metabolism,genetics Pyroptosis/genetics Interferon Regulatory Factor-1/genetics,metabolism Humans Rabbits RNA, Long Noncoding/genetics,metabolism Up-Regulation Disease Progression Male
Chemicals
MicroRNAs NLR Family, Pyrin Domain-Containing 3 Protein Interferon Regulatory Factor-1 RNA, Long Noncoding NLRP3 protein, human IRF1 protein, human
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Ma Shang
School of Osteopathy, Henan University of Chinese Medicine, 156 Jinshui East Rd, Zhengzhou 450000, China.
Yu Peng
Department of Orthopedics, The First Affiliated Hospital of Henan University of Chinese Medicine, 19 Renmin Rd, Zhengzhou 450000, China.
Ma Jinxin
School of Osteopathy, Henan University of Chinese Medicine, 156 Jinshui East Rd, Zhengzhou 450000, China.
Liu Kangnan
School of Osteopathy, Henan University of Chinese Medicine, 156 Jinshui East Rd, Zhengzhou 450000, China.
Wang Mi
Department of Rheumatology, The Third Affiliated Hospital of Henan University of Chinese Medicine, 63 Dongming Rd, Zhengzhou 450000, China.
Shi Pengbo
Department of Orthopedics, The First Affiliated Hospital of Henan University of Chinese Medicine, 19 Renmin Rd, Zhengzhou 450000, China.
Duong Nguyen Truong Duc
School of Osteopathy, Henan University of Chinese Medicine, 156 Jinshui East Rd, Zhengzhou 450000, China.
Cheng Shao
Department of Arthropathy, Henan Province Hospital of Chinese Medicine (The Second Affiliated Hospital of Henan University of Chinese Medicine), 6 Dongfeng Rd, Zhengzhou 450000, China; School of Osteopathy, Henan Province Engineering Research Center of Basic and Clinical Research of Bone and Joint Repair in Chinese Medicine, 6 Dongfeng Rd, Zhengzhou 450000, China.
Wang Shangzeng
Department of Arthropathy, Henan Province Hospital of Chinese Medicine (The Second Affiliated Hospital of Henan University of Chinese Medicine), 6 Dongfeng Rd, Zhengzhou 450000, China; School of Osteopathy, Henan Province Engineering Research Center of Basic and Clinical Research of Bone and Joint Repair in Chinese Medicine, 6 Dongfeng Rd, Zhengzhou 450000, China. Electronic address: wangsz74@163.com.
Conflict of Interest

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Article Info
Journal
International immunopharmacology
Abbr.
Int Immunopharmacol
ISSN
1878-1705
Published
2025-04-24
Epub
2025-00-19
Pages
114460
Language
English
Region
Netherlands
NLM ID
100965259
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com